the insulin may be any form or derivative of insulin that is biologically active in the animal being treated . for a human patient , the insulin is preferably human e . g ., recombinant , naturally occurring , or semisynthetic ( in which the terminal alanine of the b chain of porcine insulin is chemically replaced with threonine , to yield a molecule identical to human insulin )!, porcine , bovine , or a biologically active derivative of human insulin having certain amino acid substitutions as taught by brange et al ., diabetes care 13 : 923 , 1990 ( herein incorporated by reference ). the insulin should have a low zinc content , since zinc decreases the solubility ( and thus the dissolution rate ) of insulin , and may form insoluble precipitates with certain enhancers . the enhancer used can be any of a number of compounds which act to enhance absorption through the layer of epithelial cells lining the alveoli of the lung , and into the adjacent pulmonary vasculature . the enhancer can accomplish this by any of several possible mechanisms , including the following : ( 1 ) enhancement of the paracellular permeability of insulin by inducing structural changes in the tight junctions between the epithelial cells . ( 2 ) enhancement of the transcellular permeability of insulin by interacting with or extracting protein or lipid constituents of the membrane , and thereby perturbing the membrane &# 39 ; s integrity . ( 3 ) interaction between enhancer and insulin which increases the solubility of insulin in aqueous solution . this may occur by preventing formation of insulin aggregates ( dimers , trimers , hexamers ), or by solubilizing insulin molecules in enhancer micelles . ( 4 ) decreasing the viscosity of , or dissolving , the mucus barrier lining the alveoli and passages of the lung , thereby exposing the epithelial surface for direct absorption of the insulin . enhancers may function by only a single mechanism set forth above , or by two or more . an enhancer which acts by several mechanisms is more likely to promote efficient absorption of insulin than one which employs only one or two . for example , surfactants are a class of enhancers which are believed to act by all four mechanisms listed above . surfactants are amphiphilic molecules having both a lipophilic and a hydrophilic moiety , with varying balance between these two characteristics . if the molecule is very lipophilic , the low solubility of the substance in water may limit its usefulness . if the hydrophilic part overwhelmingly dominates , however , the surface active properties of the molecule may be minimal . to be effective , therefore , the surfactant must strike an appropriate balance between sufficient solubility and sufficient surface activity . another surfactant property that may be of importance is the net charge of the surfactant at the ph value in the lung ( approximately 7 . 4 ). the isoelectric ph of insulin is 5 . 5 . at ph 7 . 4 , insulin has a negative net charge . this results in an electrostatic repulsion between insulin molecules , which in turn prevents aggregation and thereby increases the solubility . if the surfactant also is negatively charged , yet can interact with insulin by , for example , hydrophobic interactions , additional repulsion among the insulin molecules will occur . therefore , an anionic surfactant will possess the additional advantage ( compared to those having neutral or net positive charge at physiological ph ) of enhancing absorption by helping stabilize insulin in the monomeric state . one very promising type of enhancer is the salt of a fatty acid . it has been found that the sodium salts of saturated fatty acids of carbon chain length 10 ( i . e ., sodium caprate ), 12 ( sodium laurate ) and 14 ( sodium myristate ) perform well in the method of the invention . the potassium and lysine salts of capric acid have also been found to be effective in the method of the invention . if the carbon chain length is shorter then about 8 , the surface activity of the surfactant may be too low , and if the chain length is longer than about 16 , decreased solubility of the fatty acid salt in water limits its usefulness . different counterions may change the solubility of the saturated fatty acid salt in water , such that an enhancer having a carbon length other than 8 - 16 would prove even more advantageous than the enhancers specifically mentioned hereinabove . salts of unsaturated fatty acids may also be useful in the present invention since they are more water soluble than salts of saturated fatty acids , and can therefore have a longer chain length than the latter and still maintain the solubility necessary for a successful enhancer of insulin absorption . all of the bile salts and bile salt derivatives tested ( sodium salts of ursodeoxycholic acid , taurocholic acid , glycocholic acid , and taurodihydrofusidic acid ) effectively enhance insulin absorption in the lung . examples of suitable bile salts include salts ( e . g ., sodium or potassium salts ) of cholic acid , chenodeoxycholic acid , glycocholic acid , taurocholic acid , glycochenodeoxycholic acid , taurochenodeoxycholic acid , deoxycholic acid , glycodeoxycholic acid , taurodeoxycholic acid , lithocholic acid , and ursodeoxycholic acid . preferred are the trihydroxy bile salts , such as the salts ( e . g ., potassium and sodium salts ) of cholic , glycocholic and taurocholic acids . particularly preferred are sodium taurocholate and potassium taurocholate . phospholipids were also tested as enhancers . it was found that a single - chain phospholipid ( lysophospatidylcholine ) was an effective enhancer , while two double - chain phospholipids ( dioctanoylphosphatidylcholine and didecanoylphosphatidylcholine ) were not . this may be explained by the fact that the double - chain phospholipids are much less soluble in water than their single - chain counterparts ; however , it is reasonable to expect that double - chain phospholipids of shorter chain length , having greater water - solublility than their longer chain counterparts , will be of use as enhancers in the present invention so that both single - and double - chain phospholipids may be used . examples of single - chain phospholipids include lysophosphatidylcholine , lysophosphatidylglycerol , palmitoylphosphatidylglycerol , palmitoylphosphatidylcholine , lysophosphatidylethanolamine , lysophosphatidylinositol , and lysophosphatidylserine . examples of double - chain phospholipids include diacylphosphatidylcholine , diacylphosphatidylglycerol , diacylphosphatidylethanolamine , diacylphosphatidylinositol , and diacylphosphatidylserine . one glycoside , octylglucopyranoside , was tested as an enhancer in the present invention and was found to have some absorption enhancing properties . other alkyl glycosides such as the alkyl glucosides ( e . g ., decyl glucoside , dodecyl glucoside , and alkyl thioglucopyranoside ) and alkyl maltosides ( e . g ., decyl maltoside and dodecyl maltoside ) would also be expected to exhibit absorption enhancing properties in the methods of the present invention . the cyclodextrins and derivatives thereof effectively enhance the nasal absorption of insulin , and may function similarly in the lung . dimethyl - β - cyclodextrin has been tested in the method of the present invention and has been found to have an absorption enhancing effect . other potentially useful surfactants are sodium salicylate , sodium 5 - methoxysalicylate , and the naturally occurring surfactants such as salts ( e . g ., sodium and potassium salts ) of glycyrrhizine acid , saponin glycosides , and acyl carnitines such as decanoyl carnitine , lauryl carnitine , myristoyl carnitine , and palmitoyl carnitine . for ionic enhancers ( e . g ., the anionic surfactants described above ), the nature of the counterion may be important . the particular counterion selected may influence the powder properties , solubility , stability , hygroscopicity , and local / systemic toxicity of the enhancer or of any formulation containing the enhancer . it may also affect the stability and / or solubility of the insulin with which it is combined . in general , it is expected that monovalent metallic cations such as sodium , potassium , lithium , rubidium , and cesium will be useful as counterions for anionic enhancers . ammonia and organic amines form another class of cations that is expected to be appropriate for use with anionic enhancers having a carboxylic acid moiety . examples of such organic amines include ethanolamine , diethanolamine , triethanolamine , 2 - amino - 2 - methylethylamine , betaines , ethylenediamine , n , n - dibensylethylenetetraamine , arginine , hexamethylenetetraamine , histidine , n - methylpiperidine , lysine , piperazine , spermidine , spermine , and tris ( hydroxymethyl ) aminomethane . since effective enhancement of insulin absorption in the lower respiratory tract was observed for a number of the enhancers tested , it is expected that many more will be found which also function in this manner . starch microspheres effectively enhance the bioavailability of insulin delivered via the nasal membranes and were tested as an enhancer in the methods of the invention . although they proved to be of little use for delivery via the pulmonary route in the animal model utilized herein , it is thought that this was mainly due to technical difficulties which , if overcome , may lead to successful delivery via the pulmonary route . chelators are a class of enhancers that are believed to act by binding calcium ions . since calcium ions help maintain the dimensions of the space between cells and additionally reduce the solubility of insulin , binding of these ions would in theory both increase the solubility of insulin , and increase the paracellular permeability of insulin . although one chelator tested , the sodium salt of ethylenediaminetetraacetic acid ( edta ), was found to be ineffective in enhancing absorption of insulin in the rat model tested , other calcium ion - binding chelating agents may prove to be more useful . a number of different compounds potentially useful as enhancers in the methods of the invention were tested in rats , as described in example 5 below . other substances with known absorption - enhancing properties , or with physical characteristics which make them likely candidates for use in the method of the invention , can be readily tested by one of ordinary skill in that in vivo assay , or alternatively in the in vitro assay described in example 6 . it is possible that a combination of two or more enhancer substances also gives satisfactory results . the use of such a combination in the method of the invention is considered to be within the invention . an enhancer useful in the methods of the invention will combine ( 1 ) effective enhancement of insulin absorption with ( 2 ) lack of toxicity in the concentrations used and ( 3 ) good powder properties , i . e ., lack of a sticky or waxy consistency in the solid state . toxicity of a given substance can be tested by standard means , such as an mtt assay , as for example described in int . j . pharm . 65 ( 1990 ) 249 - 259 . the powder properties of a given substance may be ascertained from published data on the substance , or empirically . in general , it is desirable to keep the ratio of insulin to enhancer as high as possible , within the range that permits fast and efficient enhancement of insulin absorption . this is important in order to minimize the risk of adverse effects , both local and systemic , attributable to the enhancer . the optimal ratio of insulin to enhancer can be ascertained for any given enhancer by testing various proportions in an in vivo model such as described herein . for example , insulin was combined with sodium caprate in the following w / w proportions : 50 / 50 , 75 / 25 , 82 . 5 / 17 . 5 , and 90 / 10 . significant improvement in absorption of insulin was obtained with 50 % and 25 % sodium caprate ; 10 % gave poor improvement in absorption , and the results with 17 . 5 % were intermediate . this indicates that the lowest effective concentration of sodium caprate for use in the methods of the invention is approximately 15 - 25 %, and probably 20 - 25 %. other enhancers may have higher or lower optimal concentrations relative to insulin . each individual enhancer must therefore be separately tested . based upon the above result , however , it is expected that the optimal proportion of a surfactant type of enhancer will generally be between 10 and 50 % of the insulin / enhancer mixture . it should be noted that the above proportions represent the proportion of enhancer relative solely to insulin , and do not take into account any excipients which may be added , for example to improve the powder properties of the formulation . the amount of insulin absorbed according to the present invention can be significantly higher than the amount absorbed in the absence of enhancer . in example 4 herein it is shown that a therapeutic preparation according to the present invention , when inhaled , exhibits a bioavailability well over three times greater than that of an inhaled preparation of insulin alone . preferably the amount of insulin absorbed according to the present invention is significantly ( p & lt ; 0 . 05 ) higher than the amount absorbed in the absence of enhancer . additive substances commonly included in therapeutic preparations , such as pharmaceutically acceptable carriers , may be included in the theraputic preparation of the present invention . additive substances may be included for example in order to dilute the powder to an amount which is suitable for delivery from the particular intended powder inhaler ; to facilitate the processing of the preparation ; to improve the powder properties of the preparation ; to improve the stability of the preparation , e . g . by means of antioxidant or ph - adjusting compounds ; or to add a taste to the preparation . any additive should not adversely affect the stability of the insulin or absorption enhancer , or disadvantageously interfere with the insulin absorption . it should also be stable , not hygroscopic , have good powder properties and have no adverse effects in the airways . as examples of potential additives may be mentioned mono -, di -, and polysaccharides , sugar alcohols and other polyols , such as for example lactose , glucose , raffinose , melezitose , lactitol , maltitol , trehalose , sucrose , mannitol and starch . as reducing sugars such as lactose and glucose have a tendency to form complexes with proteins , non - reducing sugars such as raffinose , melezitose , lactitol , maltitol , trehalose , sucrose , mannitol and starch may be preferred additives for use in the present invention . depending upon the inhaler to be used , the total amount of such additives may vary over a very wide range . in some circumstances little or no additive would be required , whereas for example in the case of an inhaler requiring large powder volumes for operation , a very high percentage of the therapeutic preparation could consist of additive . the amount of additive desirable would be easily determined by a person skilled in the art according to particular circumstances . a useful mechanism for delivery of the active compounds into the lower respiratory tract of a patient is through a portable inhaler device suitable for dry powder inhalation . many such devices , typically designed to deliver antiasthmatic or antiinflammatory agents into the respiratory system , are on the market . preferably the device is a dry powder inhaler of a design which provides protection of the powder from moisture and has no risk of occasional large doses ; in addition as many as possible of the following are desired : protection of the powder from light ; high respirable fraction and high lung deposition in a broad flow rate interval ; low deviation of dose and respirable fraction ; low retention of powder in the mouthpiece ; low adsorption to the inhaler surfaces ; flexibility in dose size ; and low inhalation resistance . the inhaler is preferably a single dose inhaler although a multi dose inhaler , preferably such as a multi dose , breath actuated , dry powder inhaler for multiple use , may be employed . preferably the inhaler used is a unit dose , breath actuated , dry powder inhaler for single use . the described powder preparation can be manufactured in several ways , using conventional techniques . it may be necessary to micronize the active compounds and , if appropriate ( i . e where an ordered mixture is not intended ), any carrier , in a suitable mill , for example in a jet mill at some point in the process , in order to produce primary particles in a size range appropriate for maximal deposition in the lower respiratory tract ( i . e ., under 10 μm ). for example , one can dry mix insulin and enhancer powders , and carrier where appropriate , and then micronize the substances together ; alternatively , the substances can be micronized separately , and then mixed . where the compounds to be mixed have different physical properties such as hardness and brittleness , resistance to micronisation varies and they may require different pressures to be broken down to suitable particle sizes . when micronised together , therefore , the obtained particle size of one of the components may be unsatisfactory . in such case it would be advantageous to micronise the different components separately and then mix them . it is also possible first to dissolve the components in a suitable solvent , e . g . water , to obtain mixing on the molecular level . this procedure also makes it possible to adjust the ph - value to a desired level . it is known that the nasal absorption of insulin is affected by the ph - value of the preparation , with increasing absorption when moving either up or down from the isoelectric point of insulin , which is around 5 . 5 . however , the insulin may be less stable at ph significantly above or below 5 . 5 , and furthermore the pharmaceutically accepted limits of ph 3 . 0 to 8 . 5 for inhalation products must be taken into account , since products with a ph outside these limits may induce irritation and constriction of the airways . to obtain a powder , the solvent must be removed by a process which retains the insulin &# 39 ; s biological activity . suitable drying methods include vacuum concentration , open drying , spray drying , and freeze drying . temperatures over 40 ° c . for more than a few minutes should generally be avoided , as some degradation of the insulin may occur . following the drying step , the solid material can , if necessary , be ground to obtain a coarse powder , then , if necessary , micronized . if desired , the micronized powder can be processed to improve the flow properties , e . g ., by dry granulation to form spherical agglomerates with superior handling characteristics , before it is incorporated into the intended inhaler device . in such a case , the device would be configured to ensure that the agglomerates are substantially deagglomerated prior to exiting the device , so that the particles entering the respiratory tract of the patient are largely within the desired size range . where an ordered mixture is desired , the active compounds may be processed , for example by micronisation , in order to obtain , if desired , particles within a particular size range . the carrier may also be processed , for example to obtain a desired size and desirable surface properties , such as a particular surface to weight ratio , or a certain ruggedness , and to ensure optimal adhesion forces in the ordered mixture . such physical requirements of an ordered mixture are well known , as are the various means of obtaining an ordered mixture which fulfills the said requirements , and may be determined easily by the skilled person according to the particular circumstances . 9 . 75 g of semisynthetic human insulin ( diosynth ) and 250 ml water is added to a beaker . the ph is lowered to 3 . 4 with 1m hcl and then raised to 7 . 4 with 1m naoh in order to dissolve the insulin . 3 . 25 g sodium caprate ( sigma ) is added and the ph is again adjusted to 7 . 4 . the solution is stirred , and when the solution is clear or weakly opalescent , it is concentrated by evaporation at 37 ° c . in about 2 days . the obtained solid cake is crushed and then sieved through a 0 . 5 mm sieve . the powder is micronized in a jet mill to particles with a mass median diameter of about 2 μm . this micronized powder , containing 75 % insulin and 25 % sodium caprate by weight , is then filled into an inhalation apparatus ( wright dust feed mechanism ) and delivered to animals . the results from an inhalation study in two non - diabetic dogs are summarized in the tables below . blood glucose and plasma insulin values were measured at the specified time intervals . table i______________________________________blood sampletime after end bloodof exposure glucose insulin conc . ( minutes ) ( mmol / l ) ( μu / ml ) ______________________________________before 3 . 9 6 . 700 . 5 3 . 6 120 . 665 2 . 8 194 . 4710 2 . 6 195 . 3920 n . d . 139 . 7422 . 5 1 . 6 n . d . 31 2 . 0 73 . 4245 1 . 7 47 . 4959 . 5 1 . 7 36 . 2189 . 5 2 . 3 19 . 28120 3 . 0 14 . 58240 4 . 5 5 . 28______________________________________ n . d . = not determined table ii______________________________________blood sampletime after end bloodof exposure glucose insulin conc . ( minutes ) ( mmol / l ) ( μu / ml ) ______________________________________before 3 . 9 44 . 843 4 . 2 165 . 106 4 . 3 158 . 2812 3 . 9 n . d . 14 n . d . 180 . 7219 3 . 0 133 . 7530 2 . 7 143 . 7145 2 . 5 91 . 6260 2 . 4 66 . 7090 2 . 7 38 . 58122 3 . 7 29 . 15241 4 . 1 n . d . 242 . 5 n . d . 19 . 76______________________________________ n . d . = not determined the tables illustrate that the insulin / sodium caprate formulation markedly increases the plasma level of insulin and decreases the blood glucose . the peak value for plasma insulin and the minimal value for blood glucose are reached after approximately 20 and 60 minutes , respectively . a preparation containing semisynthetic human insulin and sodium caprate ( 75 : 25 by weight ) was prepared as described in example 1 , and introduced into the lungs of five dogs . a control preparation containing insulin and lactose ( 8 : 92 ) but no enhancer was also prepared , and introduced into the lungs of four dogs . the total insulin dose for each dog was 1 u / kg . the effect of each formulation on plasma insulin levels and blood glucose levels was determined at various time points and the results are illustrated in fig2 and 3 . it was found that , while the control formulation containing no enhancer produced essentially no change in plasma insulin levels , the formulation containing both insulin and enhancer produced a rise in plasma insulin levels from about 20 μu / ml at time zero to about 80 μu / ml 15 min . after inhalation of the powder . likewise , the control animals registered a maximal drop in blood glucose of about 0 . 5 mmol / l following inhalation of insulin without enhancer , while the animals which inhaled insulin plus enhancer registered a transient drop of about 1 . 7 mmol / l , from about 4 . 0 mmol / l to about 2 . 3 mmol / l . thus , insulin combined with the enhancer , sodium caprate , was quickly absorbed into and cleared from the systemic circulation , with a corresponding transient decrease in blood glucose levels . in contrast , insulin with carrier ( lactose ) but no enhancer was detectably absorbed only to a very small degree . ( p = 0 . 0002 for insulin / caprate vs . insulin / lactose .) two formulations containing semisynthetic human insulin , sodium caprate and lactose combined in the ratios of 50 : 25 : 25 and 4 : 4 : 92 , respectively , and a third formulation containing human insulin and sodium caprate 75 : 25 , were prepared as described in example 1 ; in the formulations containing lactose , solid lactose was added to the insulin / sodium caprate solution prior to final ph adjustment and drying . in the experiments shown in fig4 - 7 , each of the three formulations was tested in two dogs , at the indicated dosage levels . plasma insulin and blood glucose were measured at the indicated times following inhalation of the insulin formulation . biosynthetic human insulin ( 53 g ) was micronised in an airfilco jet mill ( trade mark , airfilco process plant limited ), with pressurised nitrogen ( feed pressure 7 bar , chamber pressure 5 bar ), to a mass median diameter of 2 . 4 micrometers . sodium caprate ( 170 g ) was micronised in an airfilco jet mill ( tm ), with pressurised nitrogen ( feed pressure 5 bar , chamber pressure 3 bar ), to a mass median diameter of 1 . 6 micrometers . the micronised biosynthetic human insulin ( 45 g ) and sodium caprate ( 14 . 26 g ) were dry mixed according to the following procedure : half of the insulin was added to a mixing device comprising a mixing cylinder of volume 4 . 4 litres divided , by a sieve of width 1 mm , into two compartments , with a metal ring in each compartment to aid mixing and stirring . the sodium caprate and finally the rest of the insulin , were added . the mixing cylinder was closed , turned 180 degrees , and mounted in a motorised shaking apparatus . the motor was turned on and shaking continued for approximately two minutes , until all the insulin and sodium caprate had passed through the sieve . the motor was turned off and the mixing cylinder turned 180 degrees , again mounted on the shaking apparatus and shaking was again effected until all the powder had passed through the sieve . this procedure was repeated a further eight times to give a total mixing time of approximately 20 minutes . the preparation so obtained was administered to 5 dogs by inhalation , at a dosage level of 1 u ./ kg , and the plasma insulin level determined at various time points after administration . the results obtained were compared with the plasma insulin levels obtained when biosynthetic insulin , micronised as above to a mass median diameter of 2 . 4 micrometers , was administered to five dogs in the same way and at the same dosage levels , and with the plasma insulin levels obtained when a therapeutic preparation of insulin and sodium caprate in a ratio of 90 : 10 was administered to five dogs in the same way and at the same dosage levels as above . in this case the therapeutic preparation was prepared as follows : human semisynthetic insulin was gel filtrated to reduce the zinc content from 0 . 52 % to 0 . 01 % relative to content of insulin . insulin ( 4 . 5 g ) and sodium caprate ( 0 . 5 g ) were dissolved in water ( 232 ml ). the solution was stirred until clear and the ph adjusted to 7 . 0 . the solution was concentrated by evaporation at 37 ° c . over a period of about two days . the obtained solid cake was crushed , and sieved through a 0 . 5 mm sieve , and the resultant powder micronised through a jet mill to particles with a mass median diameter of 3 . 1 micrometers . the results of these comparisons are presented in fig1 . the results demonstrate some improvement in the bioavailability of insulin with the 90 : 10 formulation , and a dramatic improvement in the bioavailablity of insulin with the 75 : 25 preparation according to the present invention , as compared to insulin alone . ( p = 0 . 0147 for the difference between 75 : 25 and 100 : 0 ) each of the compounds listed in table iii was tested for its ability to enhance uptake of insulin , and thus affect blood glucose levels , in a rat model . various forms of insulin were employed : recombinant or semisynthetic human or bovine . each formulation was prepared as above , drying and processing the insulin / enhancer or insulin / enhancer / lactose solution to produce an inhalable powder . the powder was administered to rats by inhalation , and the blood glucose levels of the rats were subsequently monitored . these levels were compared to the corresponding values obtained from rats which had inhaled insulin formulations without enhancer . table iii______________________________________ enhancer : insulin : substance lactose effect______________________________________octylglucopyranoside 4 : 4 : 92 (+) sodium ursodeoxycholate 4 : 4 : 92 + sodium taurocholate 4 : 4 : 92 + sodium glycocholate 4 : 4 : 92 + lysophosphatidylcholine 4 : 4 : 92 + dioctanoylphosphatidylcholine 2 : 4 : 94 (+) didecanoylphospatidylcholine 4 : 4 : 94 - sodium taurodihydrofusidate 2 : 4 : 94 + sodium caprylate 25 : 75 : 0 - sodium caprate 10 : 90 : 0 (+) sodium caprate 17 . 5 : 82 . 5 : 0 (+) sodium caprate 25 : 75 : 0 + sodium caprate 4 : 4 : 92 + sodium laurate 25 : 75 : 0 (+) potassium oleate 4 : 4 : 92 + potassium caprate 27 : 73 : 0 + lysine caprate 35 : 65 : 0 + sodium myristate 30 : 70 : 0 + dimethyl - β - cyclodextrin 75 : 25 : 0 + ______________________________________ + significant decrease in blood glucose level (+) moderate decrease in blood glucose level - no or very small decrease in blood glucose level a standard in vitro assay utilizing an epithelial cell line , caco - 2 ( available through the american type culture collection ( atcc ), rockville , md ., usa ), has been developed to assess the ability of various enhancer compounds to promote transport of insulin and other markers across an epithelial cell monolayer , as a model for the epithelial cell layer which functions in the lung to separate the alveolus from the pulmonary blood supply . in this assay , the enhancer and insulin or other marker are dissolved in aqueous solution at various proportions and / or concentrations , and applied to the apical side of the cell monolayer . after 60 min incubation at 37 ° c . and 95 % rh ( relative humidity ), the amount of the marker on the basolateral side of the cells is determined : for example , by use of a radioactively labelled marker . for the particular enhancer ( sodium caprate ) tested in the experiments shown in fig6 and 7 , the amount of marker ( mannitol , mw 360 ) which appears on the basolateral side is dependent upon the concentration of enhancer used , at least up to 16 mm sodium caprate ( fig8 ). this is true even when insulin is added to the enhancer / mannitol mixture ( 1 : 3 sodium caprate : insulin , by weight ) ( fig9 ). this concentration of sodium caprate ( 16 mm ) was also found to promote absorption of insulin across the cell monolayer . the amount of insulin which passed across the monolayer doubled in the presence of 16 mm sodium caprate , compared to the amount in the absence of any enhancer . it is expected that at higher concentrations of sodium caprate , the permeability of the cells will be further increased ; however , the potential cytotoxicity of sodium caprate may prevent the use of substantially higher concentrations of this particular enhancer . this in vitro model of epithelial cell permeability can be used as a screening tool for rapidly testing any desired enhancer for usefulness in the methods of the invention .
a method of treating a patient in need of insulin treatment , including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing insulin and an enhancer compound which enhances the absorption of insulin in the lungs of the patient .